Search - tctmd.com

Displaying 81 - 100 of 3616

Sort: Relevancy | Date

Presentation TCT 2016

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Ted Feldman

November 01, 2016

Presentation TCT 2016

Portico: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Raj Makkar

November 01, 2016

Presentation TCT 2016

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Jeffrey J. Popma

November 01, 2016

Presentation TCT 2016

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., John G. Webb

November 01, 2016

News Daily News

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

Michael O'Riordan

November 01, 2016

News Conference News TCT 2016

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Presenter: Bernard J. Gersh, Felix Mahfoud

November 01, 2016

Presentation TCT 2016

Featured Lecture: Balancing the Needs for Data Transparency and the Clinical Trial Enterprise

Presenter: Robert O. Bonow, Mitchell W. Krucoff, Manesh R. Patel

November 01, 2016

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

Presentation TCT 2016

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 6-Month Angiographic and 1-Year Clinical Follow Up

Presenter: Fernando Alfonso, Ran Kornowski, Pieter R. Stella

November 01, 2016

News Industry News

Five Year Echocardiogram Follow-Up Data Demonstrates Sustained Durability After Transcatheter Aortic Valve Replacement In High-Risk And Inoperable Patients

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

News Industry News TCT 2016

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Presenter: Gregg W. Stone, Philippe Pibarot, Susheel K. Kodali

November 01, 2016

News Industry News TCT 2016

Dedicated Stent Study Conducted in Women and Minority Assesses Risks of Adverse Cardiovascular Events Following Coronary Stent Procedures

November 01, 2016

News Industry News

Sudy Indicates PCI Of NIRS-Defined Lipid-Rich Plaque Is Safe And Not Associated With A Greater Incidence Of Adverse Outcomes Compared To PCI of Non Lipid-Rich Plaque

November 01, 2016

News Conference News TCT 2016

CMR Subanalysis of EXPLORE May Help Pinpoint Which CTO Regions Benefit From PCI

Yael L. Maxwell

November 01, 2016

Presentation TCT 2016

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, David J. Cohen

November 01, 2016

Presentation TCT 2016

Prospective Single Center FIH Clinical Trial to Evaluate the Safety and Effectiveness of a Septal Occluder with Bioresorbable Framework in Patients with Clinically Significant ASD or PFO

Presenter: Ted Feldman, David Hildick-Smith, Kolja Sievert

November 01, 2016

Advertisement

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Portico: Design Features, Special Attributes, and Clinical Trial Program

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Featured Lecture: Balancing the Needs for Data Transparency and the Clinical Trial Enterprise

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 6-Month Angiographic and 1-Year Clinical Follow Up

Five Year Echocardiogram Follow-Up Data Demonstrates Sustained Durability After Transcatheter Aortic Valve Replacement In High-Risk And Inoperable Patients

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Dedicated Stent Study Conducted in Women and Minority Assesses Risks of Adverse Cardiovascular Events Following Coronary Stent Procedures

Sudy Indicates PCI Of NIRS-Defined Lipid-Rich Plaque Is Safe And Not Associated With A Greater Incidence Of Adverse Outcomes Compared To PCI of Non Lipid-Rich Plaque

CMR Subanalysis of EXPLORE May Help Pinpoint Which CTO Regions Benefit From PCI

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Prospective Single Center FIH Clinical Trial to Evaluate the Safety and Effectiveness of a Septal Occluder with Bioresorbable Framework in Patients with Clinically Significant ASD or PFO

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content